Detalhe da pesquisa
1.
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Cancer Immunol Immunother
; 73(6): 106, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634928
2.
Alpha-methyl CoA racemase (AMACR) reactivity across the spectrum of clear cell renal cell neoplasms.
Ann Diagn Pathol
; 71: 152297, 2024 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38579443
3.
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Cancer Immunol Immunother
; 72(9): 2961-2970, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37248424
4.
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Cancer Immunol Immunother
; 72(11): 3665-3682, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37676282
5.
Prognostic potential of whole exome sequencing in the clinical management of metachronous colorectal cancer liver metastases.
Cancer Cell Int
; 23(1): 295, 2023 Nov 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38008721
6.
A large-scale assay library for targeted protein quantification in renal cell carcinoma tissues.
Proteomics
; 22(7): e2100228, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34902229
7.
Octreotide in the treatment of malignant thymoma - Case report.
Rep Pract Oncol Radiother
; 25(6): 882-885, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32982594
8.
The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab.
Tumour Biol
; 39(7): 1010428317709283, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28714375
9.
Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
Tumour Biol
; 39(2): 1010428317691186, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28218046
10.
Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry.
BMC Cancer
; 17(1): 880, 2017 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29268716
11.
G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.
Tumour Biol
; 37(5): 6823-30, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26662311
12.
Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation.
Tumour Biol
; 36(8): 5801-5, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25702091
13.
High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib.
Tumour Biol
; 36(12): 9215-22, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26088452
14.
Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate.
Cancer Med
; 2024 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38164124
15.
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study.
Clin Genitourin Cancer
; 22(2): 305-314.e3, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38087702
16.
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).
Target Oncol
; 2024 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38704759
17.
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study.
Eur Urol Oncol
; 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38575409
18.
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations.
Clin Exp Metastasis
; 41(2): 117-129, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38363410
19.
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Eur Urol Oncol
; 7(1): 102-111, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37481365
20.
Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC.
J Cancer
; 14(1): 1-8, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36605490